-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

BRIEF-Dragonfly Therapeutics Says Bristol Myers Squibb Enters Into An Exclusive License For An Immunotherapy Drug Candidate

Reuters · 01/06/2023 06:07
BRIEF-Dragonfly Therapeutics Says Bristol Myers Squibb Enters Into An Exclusive License For An Immunotherapy Drug Candidate

- Bristol-Myers Squibb Co BMY.N:

  • DRAGONFLY THERAPEUTICS - BRISTOL MYERS SQUIBB EXERCISED ITS OPTION TO ENTER INTO AN EXCLUSIVE LICENSE FOR A SIXTH TRINKET IMMUNOTHERAPY DRUG CANDIDATE

  • DRAGONFLY - TO RECEIVE A $25 MILLION PAYMENT AND IS ELIGIBLE TO RECEIVE POTENTIAL FUTURE MILESTONES AND ROYALTIES ON NET SALES

Source text for Eikon: ID:

Further company coverage: BMY.N


((Reuters.Briefs@thomsonreuters.com;))